InSphero AG has acquired PhenoVista Biosciences, Inc. to strengthen its advanced 3D cell-based assay capabilities and expand translational research solutions.
InSphero AG has announced the acquisition of PhenoVista Biosciences, Inc., a strategic move aimed at expanding capabilities in advanced drug discovery, toxicology testing, and human-relevant in vitro research technologies. The acquisition combines InSphero’s expertise in three-dimensional microtissue platforms and microphysiological systems with PhenoVista’s strengths in high-content imaging, phenotypic screening, and cellular analysis.
The transaction marks a significant development for both companies as the pharmaceutical and biotechnology industries increasingly shift toward more predictive laboratory models and New Approach Methodologies (NAMs) designed to reduce dependence on traditional animal testing. By integrating complementary technologies and scientific expertise, the combined organization plans to accelerate the adoption of scalable, human-relevant workflows for drug safety and efficacy evaluation.
Based in San Diego, California, PhenoVista Biosciences has built a strong reputation within the life sciences industry for providing advanced image-based assay development and high-content analysis solutions to pharmaceutical and biotechnology customers. The company specializes in phenotypic assays, cellular imaging technologies, and complex data analysis methods that help researchers better understand biological responses during drug development.
Through the acquisition, PhenoVista will gain access to InSphero’s broader international commercial infrastructure as well as its advanced biological platforms and operational resources. The combined organization expects the integration to strengthen scientific collaboration, expand global reach, and enhance the ability to deliver next-generation translational research solutions to customers worldwide.
InSphero is widely recognized for its advanced three-dimensional microtissue systems and organotypic models, which are designed to more accurately replicate human biology compared to conventional two-dimensional cell culture systems. The company’s platforms, including its AkuraFlow™ microphysiological systems, are used in pharmaceutical research to improve prediction of drug safety, toxicity, and therapeutic efficacy during preclinical development.
By bringing together InSphero’s expertise in 3D biology and PhenoVista’s advanced imaging and analytical capabilities, the companies aim to create integrated workflows capable of generating richer and more predictive datasets earlier in the drug discovery process. The organizations believe these combined capabilities will be particularly valuable in therapeutic areas such as oncology, fibrosis, neuroscience, and drug safety assessment.
According to Jan Lichtenberg, the timing of the acquisition aligns closely with increasing momentum behind New Approach Methodologies in the United States and internationally. Regulatory agencies and research institutions have shown growing interest in replacing or reducing animal-based testing with human-relevant in vitro technologies that may provide more accurate translational data.
Lichtenberg noted that recent initiatives from the U.S. Food and Drug Administration, along with increased support from the National Institutes of Health, are helping establish a stronger foundation for broader industry adoption of advanced in vitro testing systems. He stated that the combination of InSphero and PhenoVista positions the organization to support this transition with scalable and commercially ready technologies designed for modern pharmaceutical research.
The increasing focus on NAMs reflects broader changes occurring across the life sciences industry. Pharmaceutical companies are under growing pressure to improve predictive accuracy during preclinical development while reducing costs, accelerating timelines, and minimizing late-stage clinical failures. Human-relevant in vitro systems, including 3D microtissues, organ-on-chip platforms, and advanced imaging technologies, are increasingly viewed as important tools for addressing these challenges.
PhenoVista’s expertise in high-content imaging and phenotypic analysis adds a powerful analytical dimension to InSphero’s biological platforms. High-content imaging technologies allow researchers to capture detailed cellular and molecular information from complex biological systems, generating large datasets that can reveal subtle treatment effects and disease mechanisms. Combined with artificial intelligence-driven analytics, these approaches may improve the ability to identify promising therapeutic candidates earlier in the drug development process.
James G. Evans described the acquisition as an important opportunity for PhenoVista, its employees, and its customers. He emphasized that both companies share a common vision focused on advancing drug discovery through innovative assay technologies, sophisticated analytics, and artificial intelligence-enabled research tools.
According to Evans, integrating PhenoVista’s imaging and assay development capabilities with InSphero’s scalable 3D biology platforms will allow the combined organization to deliver greater scientific value and broader technical capabilities to customers globally. He suggested that the partnership could significantly enhance the depth and quality of translational research services available to pharmaceutical and biotechnology companies.
The acquisition is also expected to create operational benefits for customers. By combining expertise and infrastructure, the organizations anticipate improving turnaround times for research projects, strengthening scientific collaboration with clients, and increasing access to advanced NAMs technologies in the rapidly expanding in vitro testing market.
As demand grows for more predictive preclinical testing systems, integrated workflows that combine advanced biology, imaging, and computational analytics are becoming increasingly important. Drug developers are seeking technologies capable of producing more comprehensive biological insights while supporting faster and more informed decision-making throughout discovery and development programs.
The combined InSphero and PhenoVista organization plans to leverage artificial intelligence and machine learning approaches alongside complex biological models to generate multidimensional datasets that may improve understanding of disease biology, drug mechanisms, and toxicity risks. Such approaches are increasingly viewed as essential for the future of precision medicine and translational drug development.
The acquisition also highlights the growing convergence between biological modeling technologies and advanced data science within the pharmaceutical research ecosystem. As modern drug discovery generates increasingly large and complex datasets, companies capable of integrating biological relevance with sophisticated analytical capabilities are likely to become more valuable partners to the industry.
In oncology research, for example, the combination of 3D tumor models with high-content imaging may help researchers better evaluate tumor behavior, treatment responses, and microenvironment interactions. In fibrosis and neuroscience, integrated phenotypic analysis platforms may enable more detailed investigation of disease progression and therapeutic mechanisms. Meanwhile, safety assessment programs may benefit from improved prediction of toxicity and off-target effects before clinical testing begins.
Industry observers have noted that acquisitions such as this reflect broader investment trends in translational research technologies and advanced in vitro systems. Regulatory support, scientific advancements, and pharmaceutical demand are collectively driving increased adoption of human-relevant testing platforms designed to improve efficiency and reliability in drug development.
By uniting complementary expertise in 3D biology, imaging, phenotypic screening, and artificial intelligence-enabled analytics, InSphero and PhenoVista aim to position themselves at the forefront of this evolving market. The combined company intends to support pharmaceutical and biotechnology partners with integrated solutions capable of accelerating discovery timelines while improving the predictive value of preclinical research.
As the life sciences industry continues transitioning toward more human-centered testing approaches, the acquisition may strengthen the ability of both organizations to contribute to the next generation of drug discovery and translational medicine technologies.
About InSphero
InSphero is the only 3D, in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow for more effective and safe therapies to get to the clinic faster due to our superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to inspire the next generation of breakthrough therapies through customer engagement, commitment to innovation, and the model of excellence.
About PhenoVista Biosciences
PhenoVista is a contract research organization (CRO) and leading provider of both custom and off-the-shelf, imaging-based assay services based in San Diego, California. They develop and execute disease-relevant, cell-based assays by working with clients in a collaborative, adaptable manner. PhenoVista provides high-quality data to biopharmaceutical clients of all stages and sizes with its unique combination of cutting-edge cell models and the latest high-content imaging technologies and data-analysis capabilities. Their diverse repertoire includes working with primary cells, iPSC-derived neurons and glia, and client-engineered lines in a variety of formats.
